Survodutide vs MGF (Mechano Growth Factor)
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideAnabolic & IGF
MGF (Mechano Growth Factor)- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
- Half-Life
- ~7 days
- Native MGF: minutes. PEG-MGF: ~3 days
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 200–400 mcg
- Frequency
- Once weekly
- 1–2 times per week
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Activates muscle satellite cells for repair and growth
- Accelerates recovery from muscle damage
- Synergistic with IGF-1 LR3 (different mechanisms)
- Promotes muscle hypertrophy specifically at exercised muscles
- Faster recovery between training sessions
- Potential for injury repair in connective tissue
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Muscle soreness (satellite cell activation)
- Injection site irritation
- Hypoglycemia risk (modest, less than IGF-1 LR3)
- Stacks With
- —
- —